CONCLUSION
vaginal itching
ADVERSE EFFECTS, MVP
The incidence of positive pregnancy tests, clinical pregnancies, and ongoing pregnancy rates in women that used oral DYD for LPS during IVF–ET was similar to that of women who used MVP pessary. Similarly, the tolerability of the drugs did not differ between the two groups except for vaginal itching, which was expressively greater in the MVP when compared to the DYD group. It appears less expensive to use DYD than MVP for LPS. When available, oral DYD can safely be used for LPS in the IVF-ET cycles. This study validates oral DYD as a feasible alternative to MVP pessary because of its similar pregnancy rates and fewer adverse effects. Since the oral route is user-friendly and DYD appears cheaper, DYD may continue to replace MVP pessary as the LPS of choice among women undergoing IVF-ET.